31
METHOD OF REMOVING AN INFLATED IMPLANT FROM A BLADDER. March 9, 2017: US20170065160-A1

An inflated implant, such as an attenuation device, previously implanted in a urinary bladder can later be removed according to a number of different methods. Preferably, removal is accomplished transurethrally. In one embodiment, removal is accomplished by reducing the inflated implant from an enla ...


32
METHOD OF REMOVING AN INFLATED IMPLANT FROM A BLADDER. March 23, 2017: US20170079761-A1

An inflated implant, such as an attenuation device, previously implanted in a urinary bladder can later be removed according to a number of different methods. Preferably, removal is accomplished transurethrally. In one embodiment, removal is accomplished by reducing the inflated implant from an enla ...


33
FUMARATE ESTER PHARMACEUTICAL COMPOSITIONS. April 13, 2017: US20170100360-A1

Described herein are pharmaceutical compositions comprising fumarate esters, methods for making the same, and methods for treating subjects in need thereof. In particular, oral pharmaceutical compositions comprising fumarate esters are described.


34
FUMARATE ESTER DOSAGE FORMS. April 13, 2017: US20170100361-A1

Described herein are pharmaceutical compositions comprising fumarate esters, methods for making the same, and methods for treating subjects in need thereof. In particular, oral controlled release pharmaceutical compositions comprising fumarate esters suspended in liquid matrices are described. One e ...


35
FUMARATE ESTER DOSAGE FORMS. April 13, 2017: US20170100362-A1

Described herein are pharmaceutical compositions comprising fumarate esters, methods for making the same, and methods for treating subjects in need thereof. In particular, oral controlled release pharmaceutical compositions comprising fumarate esters suspended in liquid matrices are described. One e ...


36
LIQUID FORMULATION OF A FUSION PROTEIN COMPRISING TNFR AND FC REGION. February 2, 2017: US20170028020-A1

The present invention relates to a liquid formulation comprising a TNFR-Fc fusion protein and a stabilizer, in which the fusion protein comprises TNFR (tumor necrosis factor receptor) or a fragment thereof and an immunoglobulin Fc region, and the stabilizer comprises one or more amino acids selected ...


37
BIOFILM PREVENTION, DISRUPTION AND TREATMENT WITH BACTERIOPHAGE LYSIN. May 11, 2017: US20170127683-A1

The present invention provides methods for the prevention, control, disruption and treatment of bacterial biofilms with lysin, particularly lysin having capability to kill Staphylococcal bacteria, including drug resistant Staphylococcus aureus, particularly the lysin PlySs2. The invention also provi ...


38
MEDICAL DEVICE AND METHOD FOR PROVIDING INFORMATION FOR GLYCEMIC CONTROL. May 25, 2017: US20170143901-A1

A medical device for providing information for glycemic control is provided, wherein the device comprises storage means arranged to store data, receiving means arranged to receive blood glucose value data and security data, data processing means arranged to execute a first processing function for mo ...


39
June 8, 2017: US20170159015-A1

One form of the present invention is directed to a method of remyelinating demyelinated axons by treating the demyelinated axons with oligodendrocyte progenitor cells under conditions which permit remyelination of the axons. Another aspect of the present invention relates to a method of treating a s ...


40
Endothelial-targeted Adenoviral Vectors, Methods and Uses Therefor. Washington University, June 8, 2017: US20170159072-A9

Disclosed are adenovirus vectors comprising a ROBO4 enhancer/promoter operatively linked to a transgene. Also disclosed are adenovirus vectors comprising a chimeric AD5-T4 phage fibritin shaft, a trimerization domain displaying a myeloid cell-binding peptide (MBP), and a ROBO4 enhancer promoter oper ...



Click the thumbnails below to visualize the patent trend.